Stada ‘Continuously Evaluating’ OTC Deals As Sales Grow Double Digits

摘要

Acquiring in July a basket of six OTC brands from GlaxoSmithKline PLC has not sated Stada Arzneimittel AG’s appetite for further deals to grow its consumer health-focused Branded Products division. The Germany-based frm told HBW Insight that it was “continuously evaluating OTC acquisitions” in line with its strategy of “rapid expansion” at Branded Products.